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Purpose: To investigate the frequency and phenotypic and functional characteristics of S-antigen (S-Ag) specific T cells
in patients with Behcet’s disease (BD).
Methods: Blood was taken from 23 active BD patients, 12 inactive BD patients, and 14 healthy controls. The clinical
features of the patients were summarized. T cell response against 40 mixed S-Ag peptides was identified by interferon
gamma  (IFN-γ)  enzyme-linked  immunospot  assay  (ELISPOT).  CD69  and  CD45RO were used  to characterize the
phenotype of S-Ag specific T cells. The functional property of S-Ag specific T cells was investigated by measuring the
production of cytokines.
Results: Response to the mixed S-Ag peptides was found in 56.5% and 25% of active and inactive BD patients,
respectively. The responsiveness to S-Ag peptides was unrelated to the clinical features of the patients. About 65.8% of
IFN-γ+ CD4+ T cells in active BD patients expressed CD69 and CD45RO concomitantly. S-Ag peptides significantly
induced a production of IFN-γ and tumor necrosis factor (TNF)-α but not interleukin (IL)-2, IL-4, and IL-17 by peripheral
blood mononuclear cells (PBMCs) in active BD patients with a response to S-Ag.
Conclusions: S-Ag specific T cells are present in certain active BD patients, and most of them are activated memory
CD4+ T cells. These T cells may be involved in the pathogenesis of BD via producing Th1-dominant cytokines.
Behcet’s  disease  (BD)  is  a  chronic,  relapsing,
multisystem inflammatory disorder characterized by recurrent
episodes  of  severe  intraocular  inflammation,  oral  ulcers,
genital  ulcers,  and  skin  lesions.  Extensive  studies  have
provided accumulating evidence to support the notion that
autoimmune response plays a major role in its pathogenesis
[1-3].  However,  studies  on  autoantigen-induced  cellular
immune responses in patients with BD have mainly used
assays  that  measure  the  lymphoproliferative  response.
Arrestin,  a  48  kDa  soluble  retinal  antigen  (S-Ag),  is  an
extremely  potent  uveitogenic  antigen  among  various
candidate antoantigens in BD [4]. Lymphocyte proliferative
responses  to  S-Ag  or  peptides  derived  from  it  have  been
reported to be present in a variety of human uveitis entities,
including BD [5-8]. Nevertheless, the autoantigens used in
most of these studies are homologous bovine proteins because
it is difficult to obtain sufficient amounts of the native human
protein. It is uncertain whether the epitopes from bovine S-Ag
are identical with those from the human protein [5]. Studies
by Doekes et al. [9], for instance, showed that sera from human
uveitis patients showed preferential reactivity to human S-Ag
while  being  very  weakly  reactive  with  bovine  S-Ag.
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Additionally,  the  functional  features  such  as  cytokine
secretion of autoreactive T cells against human S-Ag in human
uveitis have not been investigated.
In this study, we synthesized human S-Ag overlapping
peptides  as  the  antigen  and  adopted  enzyme-linked
immunospot assay (ELISPOT), intracellular cytokine staining
(ICS),  and  enzyme-linked  immunosorbent  assay  (ELISA)
techniques  to  investigate  the  frequency,  phenotype,  and
functional feature of S-Ag specific T cells in BD patients.
METHODS
Subjects: Thirty-five male BD patients with an average age of
31 years were recruited from the Uveitis Study Center of Sun
Yat-sen  University  (Guangzhou,  Guangdong,  China).
Fourteen healthy male individuals with an average age of 33
years were used as the controls. All BD patients met the
diagnostic criteria established by the International Behcet’s
Disease  Study  Group  [10].  Twenty-three  patients  treated
irregularly before being referred to the Uveitis Study Center
showed active recurrent uveitis as evidenced by dust keratic
precipitates (100%), flare and cells in the anterior chamber
(100%),  hypopyon  (17.4%),  vitreous  cells  (47.8%),  and
retinal  vasculitis  observed  clinically  or  disclosed  by
fluorescein angiography (100%). The exact treatment history
of these patients could not be retrieved. Besides recurrent oral
ulceration, these active BD patients had at least one of the
following extraocular manifestations: multiform skin lesions
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1456(69.6%),  recurrent  genital  ulceration  (34.8%),  arthritis
(21.7%), and a positive pathergy test (17.4%). They were
treated  with  low  dose  prednisone  (20  mg/day  or  less)  or
without systemic treatment at the time of blood sampling.
Twelve  patients  who  showed  neither  active  intraocular
inflammation  nor  extraocular  findings  for  at  least  three
months  after  treatment  with  immunosuppressive  agents
(prednisone 5–20 mg/day and cyclosporine A 2.0–4.0 mg/kg/
day or in combination with one of the following medicines
including cyclophosphamide 50 mg/day, chlorambucil 2 mg/
day, and colchicine 0.5 mg/day) at the Uveitis Study Center
were defined as inactive BD patients. These patients had also
suffered panuveitis (100%), hypopyon (25%), recurrent oral
ulceration (100%), multiform skin lesions (66.7%), recurrent
genital ulceration (58.3%), arthritis (25%), a positive pathergy
test (41.7%), and epididymitis (16.7%) before our treatment.
Sampling was performed from the BD patients and healthy
controls after they had given their informed, written consent.
All procedures were approved by the ethics committee of the
Zhongshan  Ophthalmic  Center  (Guangzhou,  Guangdong,
China).
Peptides  synthesis  and  preparation:  Forty  overlapping
peptides spanning the entire length of human retinal S-Ag
sequence (P10523) were synthesized by Shanghai Sangon
Biologic  Engineering  Technology  &  Services  Company
(Shanghai, China). Each peptide determinant measured 20
amino  acids  (aa)  in  length  and  overlapped  the  previous
sequence by 10 aa except for the last one that measured 15 aa.
These peptides were synthesized by conventional solid-phase
chemistry and purified by reverse-phase high-performance
liquid chromatography to at least 95% purity. The endotoxin
levels of the forty peptides were less than 0.001 ng/μg as
determined by the Limulus amebocyte lysate assay.
A series of concentrations including 50, 20, 10, 5, and
1  μg/ml  of  peptides  were  used  in  the  ELISPOT  assay  in
preliminary experiments. The results showed that an optimal
concentration was obtained at a concentration of 5 μg/ml, and
we  therefore  used  this  concentration  in  the  following
experiments.
Isolation of peripheral blood mononuclear cells: Peripheral
venous  blood  was  drawn  in  a  heparinized  tube  from  all
subjects. Peripheral blood mononuclear cells (PBMCs) were
isolated  immediately  by  Ficoll–Hypaque  density  gradient
centrifugation  (Pharmacia  Biotech,  Shanghai,  China)  and
suspended  at  2×106  cells/ml  in  complete  culture  medium
(RPMI  1640  containing  10%  fetal  calf  serum,  100  U/ml
penicillin, and 100 mg/ml streptomycin).
Interferon (IFN)-γ ELISPOT assay: The interferon (IFN)-γ
ELISPOT  assay  was  performed  using  a  commercially
available kit (BD PharMingen, San Diego, CA) according to
the  manufacturer’s  instructions.  In  this  study,  a  total  of
2×105 fresh PBMCs were added to microwells in triplicate and
incubated  with  S-Ag  peptides  plus  1  μg/ml  anti-CD28
monoclonal antibody (mAb; Clone CD28.2, BD PharMingen)
for 20 h. PBMCs stimulated with 10 ng/ml anti-CD3 (Clone
HIT3a,  BD  PharMingen)  plus  1  μg/ml  anti-CD28  mAbs
served  as  positive  controls.  Results  of  preliminary
experiments showed that there was no difference in IFN-γ
production by PBMCs stimulated with or without 1 μg/ml
anti-CD28  mAb.  In  further  experiments  for  this  study,
PBMCs  cultured  alone  were  therefore  used  as  negative
controls.
The  spots  were  counted  automatically  using  an
ImmunoSpot Image Analyzer (Cellular Technology Limited,
Cleveland,  OH).  Digitized  images  were  analyzed  for  the
presence of areas in which color density exceeds background
by  an  amount  set  on  the  basis  of  the  comparison  of
experimental wells and negative control wells. A spot called
spot-forming cell (SFC) represented an IFN-γ producing cell.
The number of spots in negative control wells was at a range
of no spots to two spots. Wells containing more than two spots
were considered as showing a positive response.
Cytokines assay by ELISA: PBMCs were stimulated with the
mixed S-Ag peptides plus 1 μg/ml anti-CD28 mAb for 72 h
at a density of 2×106 cells/ml. The PBMCs, which were not
stimulated, served as negative controls. The levels of IFN-γ,
interleukin (IL)-2, TNF-α, IL-4, and IL-17 in cell culture
supernatants  were  detected  using  the  Duoset  ELISA
Development Kit (R&D system, Minneapolis, MN) according
to the manufacturer's instruction. The lower detection limit for
the IFN-γ, IL-2, TNF-α, and IL-17 assay kit was 15.6 pg/ml
and for IL-4 was 31.2 pg/ml.
Intracellular cytokine staining and flow cytometry analysis:
In  vitro  PBMC  stimulation  with  antigen  and  intracellular
cytokine staining were generally performed according to the
method described by Waldrop et al. [11]. Since S-Ag specific
T cells were not detectable after 6 h incubation, a longer
incubation time (20 h) was employed for this experiment
[12]. PBMCs were stimulated with peptides plus anti-CD28
mAb as described above. The unstimulated PBMCs were used
as  negative  controls.  After  a  20  h  stimulation,  3  μg/ml
brefeldin A (eBioscience, San Diego, CA) was added for an
additional  4  h  incubation  to  inhibit  protein  transport  of
cytokines.  The  PBMCs  were  incubated  with  PerCP-
conjugated anti-CD3 (BD PharMingen), PeCy7-conjugated
anti-CD8  (eBioscience),  FITC-conjugated  anti-CD69
(eBioscience) and allophycocyanin (APC)-conjugated anti-
CD45RO (eBioscience) for 30 min in the dark at 4 °C. For
intracellular IFN-γ detection, the cells were then fixed with
4% paraformaldehyde for 8 min at room temperature and
permeabilized with 0.1% saponin (permeabilization buffer,
eBioscience)  overnight  at  4  °C  and  stained  with  PE-
conjugated  anti-IFN-γ  (eBioscience)  or  matched  isotype
control mAb (eBioscience) for 30 min at 4 °C. The samples
were subjected to flow cytometry, and 600,000 events were
collected for analysis using CellQuest 4.3 software (Becton
Dickinson, San Jose, CA).
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1457Statistical  analysis:  Data  were  analyzed  using  statistical
software  SPSS  10.0  (SPSS  Inc.,  Chicago,  IL).  Data  are
expressed as mean±SD. Statistical analysis was performed
using  Student’s  t-test,  one-way  ANOVA,  and  Pearson
correlation  assay.  A  level  of  p<0.05  was  considered
significant.
RESULTS
Specific T cell immune response to S-Ag in Behcet’s disease
patients: The first set of experiments was done to identify the
specific T cell response to human S-Ag in BD patients and
healthy controls using the IFN-γ ELISPOT assay. PBMCs
were stimulated with S-Ag synthetic peptides plus anti-CD28
TABLE 1. CLINICAL FEATURES OF PATIENTS WITH BEHCET’S DISEASE AND THE RESPONSIVENESS OF PERIPHERAL BLOOD
MONONUCLEAR CELLS AGAINST S-AG PEPTIDES STIMULATION.
Patient
number
  Age
(years) Diagnosis
Special ocular
manifestations
Extraocular
symptoms
Response
 to S-Ag
1 35 active BD *, ** Positive
2 30 active BD vitreous cells *, ** Positive
3 20 active BD vitreous cells *, **, ***, ## Positive
4 17 active BD hypopyon, vitreous cells *, ***, # Positive
5 25 active BD vitreous cells *, ** Positive
6 16 active BD vitreous cells *, ** Positive
7 27 active BD hypopyon, vitreous cells *, ** Positive
8 24 active BD vitreous cells *, ***, # Positive
9 22 active BD *, ** Positive
10 29 active BD *, ** Positive
11 36 active BD *, ## Positive
12 44 active BD *, *** Positive
13 26 active BD *, **, ## Positive
14 17 active BD vitreous cells *, **, *** Negative
15 40 active BD hypopyon, vitreous cells *, **, ***, ## Negative
16 33 active BD *, *** Negative
17 27 active BD *, ## Negative
18 24 active BD *, # Negative
19 25 active BD vitreous cells *, **, # Negative
20 19 active BD *, ** Negative
21 36 active BD hypopyon, vitreous cells *, ** Negative
22 29 active BD *, **, *** Negative
23 28 active BD *, ** Negative
24 42 inactive BD *, ***, ## Positive
25 29 inactive BD hypopyon *, ** Positive
26 37 inactive BD *, ** Positive
27 41 inactive BD *, **, *** Negative
28 34 inactive BD *, **, #, ##, ### Negative
29 44 inactive BD hypopyon *, **, ***, #, ## Negative
30 39 inactive BD *, ** Negative
31 47 inactive BD *, # Negative
32 32 inactive BD hypopyon *, **, ***, # Negative
33 34 inactive BD *, *** Negative
34 34 inactive BD *, *** Negative
35 39 inactive BD *, **, ***, #, ### Negative
In the “Extraocular symptoms” column, the asterisk indicates recurrent oral ulceration, the double asterisk designates multiform
skin  lesions, the triple asterisk indicates recurrent genital ulceration, the sharp (hash mark) shows a positive pathergy test, the
double sharp designates arthritis, and the triple sharp indicates epididymitis.
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1458mAb. In terms of the IFN-γ SFC, 56.5% (13/23) of active BD
patients and 25% (3/12) of inactive BD patients showed a
response to these peptides with a mean SFC frequency of
12.6/2×105  (SD=5.0  /  2×105)  and  11.3/2×105  (SD=4.2  /
2×105), respectively. No healthy controls showed a positive
response  to  these  peptides  (SFC  0.2±0.4/2×105).  The
frequency of IFN-γ producing cells in active BD patients was
similar  to  that  observed  in  the  inactive  individuals.  The
responsiveness of PBMCs to S-Ag peptides seemed not to be
affected by ocular involvement or systemic involvement in
these patients (Table 1).
To further investigate the role of S-Ag specific T cells in
uveitis with BD, we divided the active BD patients into two
groups according to their responsiveness to S-Ag peptides,
active BD patients with a response to S-Ag (n=13) and active
BD patients without a response to S-Ag (n=10). Upon the
stimulation of anti-CD3 mAb, the active BD patients both
with  and  without  a  response  to  S-Ag  produced  a  higher
frequency  of  IFN-γ  producing  cells  than  healthy  controls
(with;  p<0.001,  without;  p=0.001)  and  the  inactive  BD
patients (with; p<0.001, without; p<0.001). No difference was
found between active BD patients with or without a response
to S-Ag (Figure 1).
Phenotypic characterization of S-Ag specific T cells in active
Behcet’s disease patients: To determine which cell population
is involved in the S-Ag specific immune response and to
characterize their phenotype, PBMCs from the active BD
patients with a response to S-Ag were examined by five-color
flow  cytometry  (FCM).  The  expressions  of  CD69+  and
CD45RO+ on IFN-γ producing cells were explored in CD4+
and  CD8+  T  cells,  respectively  (Figure  2A).  The  IFN-γ
producing cells were detectable only in six of these patients
by FCM. Increased IFN-γ producing CD4+ T cells specific to
S-Ag  were  detected  with  a  mean  frequency  of  0.0177%
(range:  0.0111%–0.0262%)  after  stimulation  with  S-Ag
peptides. In this subset, 83.3% (range: 76.5%–87.5%), 69.8%
(range: 50%–81.8%), and 64.3% (range: 50%–75.76%) were
activated T cells, memory T cells, and activated memory T
cells, respectively. There was no difference in the frequency
of CD8+ IFN-γ+ T cells between stimulated and unstimulated
PBMCs  (Figure  2B).  After  stimulation,  80.8%±17.8%  of
CD8+ IFN-γ+ T cells were early nonactivated T cells and
37.3%±18.2% of them were memory T cells.
Pattern of cytokine production by S-Ag specific T cells: To
investigate the functional property of S-Ag specific T cells,
various cytokine levels representing the function of T helper
type (Th) 1/ Th2/ Th17 in culture supernatants of PBMCs from
BD patients and healthy controls were measured by ELISA.
The  level  of  IFN-γ  in  culture  supernatants  of  PBMCs
stimulated with S-Ag peptides was significantly higher than
that without stimulation in active BD patients with response
to  S-Ag  (p=0.008;  Figure  3A).  Although  the  PBMCs
produced a somewhat increased amount of IFN-γ upon the
stimulation of S-Ag peptides in healthy controls, active BD
patients without a response to S-Ag, and inactive BD patients,
there was no difference in the IFN-γ levels between stimulated
Figure  1.  The  frequency  of  IFN-γ
producing cells detected by ELISPOT
assay. Fresh PBMCs were cultured with
mixed  S-Ag  peptides  plus  anti-CD28
mAb. PBMCs cultured with the medium
and  anti-CD3  plus  anti-CD28 mAbs,
respectively, were used as negative and
positive controls. If the value of IFN-γ
SFC  was  more  than  2,  then  it  was
considered a positive well. Upon S-Ag
peptides  stimulation,  13  active  BD
patients and three inactive BD patients
showed  a  positive  response  and  the
frequency of S-Ag specific T cells was
similar  between  the  two  groups  of
patients (p>0.05, Student’s t-test). Upon
anti-CD3  stimulation,  all  the  subjects
responded positively and the number of
IFN-γ  SFC  was  larger  than  that
stimulated  by  S-Ag  peptides.  The
frequencies of IFN-γ producing cells in
four groups of PBMCs upon anti-CD3
stimulation were analyzed by ANOVA.
Significant statistical difference was set
at p<0.05 (*) and p<0.01 (#); ns means
not  significant  while  bars  represent
mean values.
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1459and unstimulated PBMCs from these patients. Moreover, after
stimulation,  the  IFN-γ  level  in  active  BD  patients  with  a
response to S-Ag was higher than that in the other three groups
(p=0.006, p=0.033, and p=0.005, respectively). These results
confirm  the  S-Ag  specific  response  at  a  global  level  and
demonstrate that the mixed S-Ag peptides are immunogenic
in certain BD patients.
TNF-α levels in healthy controls, active BD patients with
a response to S-Ag, active BD patients without a response to
S-Ag, and inactive BD patients were all elevated in response
to stimulation of S-Ag peptides (p=0.001, p=0.025, p=0.033,
and p=0.028, respectively; Figure 3B). Furthermore, TNF-α
levels in active BD patients with a response to S-Ag was
higher than that in healthy controls (p=0.025) or inactive BD
patients (p=0.002). The TNF-α levels in active BD patients
with a response to S-Ag was identical to that observed in
active BD patients without a response to S-Ag. As for IL-17,
there was a basal secretion by PBMCs from both BD patients
and healthy controls (Figure 3C). Upon stimulation with S-
Ag peptides, the IL-17 level was not significantly elevated in
any of the subjects and the level was similar in active BD
patients with and without a response to S-Ag. IL-2 and IL-4
were undetectable in all subjects.
In view of the fact that IFN-γ, TNF-α, and IL-17 can be
secreted  by  PBMCs  stimulated  with  S-Ag  peptides,  we
analyzed the relationships between IFN-γ and TNF-α or IL-17
upon S-Ag stimulation in healthy controls, active BD patients
with a response to S-Ag, active BD patients without a response
to S-Ag, and inactive BD patients were analyzed, respectively.
An analysis of Pearson correlation showed that there was no
statistical correlation between IFN-γ and TNF-α or between
IFN-γ and IL-17. However, certain tendencies were observed.
In active BD patients with a response to S-Ag, the trend
showed that IFN-γ was positively correlated with TNF-α and
negatively correlated with IL-17 while in active BD patients
without a response to S-Ag, the postive correlative trends were
observed between IFN-γ and TNF-α or between IFN-γ and
TNF-α.
DISCUSSION
This pilot study investigated the cellular immune response to
human S-Ag at both the single cell level and the global level
in BD patients with or without active uveitis. As BD is male
predominant and the male patients often have severe uveitis
compared with the female patients [13,14], we only selected
male BD patients as the subjects to avoid the interference of
hormones  in  the  study.  Since  the  acknowledged
immunodominant epitope of human S-Ag is uncertain, we
Figure 2. Phenotype of S-Ag specific T
cells detected by intracellular cytokine
staining.  PBMCs  from  the  active  BD
patients with a response to S-Ag were
cultured with or without mixed S-Ag
peptides plus anti-CD28 mAb and then
were stained and examined by five color
FCM.  Lymphocytes  were  first  gated
using Forward Scatter (FSC) combined
with Side Scatter (SSC), and then the
CD3+CD8- and CD3+CD8+ cells were
gated for analyzing the expression of
IFN-γ  in  CD4+  T  cells  and  the
expression of IFN-γ in CD8+ T cells.
Lastly,  the  expressions  of  CD69  and
CD45RO  molecules  on  IFN-γ+CD4+
and IFN-γ+CD8+ T cells were analyzed,
respectively.  A:  The  charts  show  the
phenotypic feature of S-Ag specific T
cells  of  one  representative  active  BD
patient.  B:  The  chart  represents  the
expression of IFN-γ as the percentage of
total  CD4+  or  CD8+  T  cells  in  six
different patients. Data were analyzed
by Student’s t-test.
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1460Figure 3. Functional property of S-Ag
specific T cells disclosed on the basis of
cytokine  secretion.  PBMCs  from  all
subjects were stimulated with or without
mixed S-Ag peptides plus anti-CD28 for
72  h.  The  culture  supernatants  were
collected  and  assessed  for  the
production  of  IFN-γ  (A),  TNF-α  (B),
and IL-17 (C) by ELISA. The difference
in cytokine levels between the negative
control  and  S-Ag  stimulation  in  four
groups was analyzed using Student’s t-
test.  The  cytokine  production  by
PBMCs upon S-Ag stimulation in each
of  the  four  groups  was  analyzed  by
ANOVA.  Significant  statistical
difference  was  set  at  p<0.05  (*)  and
p<0.01  (#);  ns  means  not  significant
while bars represent mean values.
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1461used a panel of overlapping peptides as the antigen to identify
specific immune response in these patients. We found that S-
Ag specific T cells existed in most active BD patients and a
few of the inactive patients. Most autoreactive T cells to S-Ag
were  activated  memory  CD4+  T  cells.  The  study  on  the
functional properties revealed that S-Ag peptides induced a
production of IFN-γ and TNF-α but not IL-17 in active BD
patients with a response to S-Ag.
Cellular proliferative response to S-Ag or S-Ag peptides
have  been  described  in  BD  patients  [6,8]  whereas  the
autoimmunity against S-Ag based on cytokine-secreting has
not been reported in patients with uveitis. The ELISPOT assay
has proven to be an optimal technique for assessing antigen
specific cells at a single cell level, which could display one
target cell among one million cells [15,16]. Since IFN-γ was
the key cytokine in S-Ag mediated uveitis [12,17], we applied
the IFN-γ ELISPOT assay in this study to measure the cellular
immune response to S-Ag in BD patients and to enumerate
the frequency of S-Ag specific T cells. We further quantitated
the reactivity by ELISA at the global level. Our data showed
that more than one-half of the active BD patients and a quarter
of the inactive BD patients responded to the mixed S-Ag
peptides  at  a  low  frequency  of  autoreactive  T  cells.  This
response  was  observed  in  less  than  30%  of  active  Vogt-
Koyanagi-Harada syndrome patients (data not shown) and
none of the healthy controls. The proportion of the positive
response to S-Ag is in agreement with the results presented
by Yamamoto et al. [6]. They found that 61% of BD patients
with uveitis and 29% of BD patients without uveitis responded
to  bovine  S-Ag  and  30%  of  healthy  controls  displayed  a
weakly positive reactivity. The negative responses shown by
ELISPOT assay in all healthy controls may justify that it is
more  specific  than  the  proliferation  assay.  Interestingly,
although we found a similar frequency of S-Ag specific T cells
in inactive and active BD patients, the IFN-γ level measured
by ELISA in inactive patients was significantly lower than
that observed in active patients. ELISPOT detects the cells as
soon  as  they  begin  to  secrete  the  specific  cytokine  upon
antigen  stimulation  while  ELISA  measures  the  cytokine
concentration in the cell culture supernatant, which sometimes
has  a  bias  due  to  minimal  synthesis  and/or  cytokine
consumption  [18].  The  S-Ag  specific  T  cells  in  inactive
patients may produce minimal IFN-γ at the global level, which
is  attributed  to  their  functional  inhibition  by
immunosuppressive agents. Therefore, the IFN-γ level was
discrepant between ELISA and ELISPOT measurement in
these patients. With regard to the anti-CD3 stimulation, active
BD patients produced a higher frequency of IFN-γ producing
cells than healthy controls and inactive BD patients, which
may  show  that  active  BD  patients  were  in  an  enhanced
immune state. The result that the number of IFN-γ producing
cells in active BD patients was equal whether they responded
to S-Ag peptides or not may suggest that varied mechanisms
besides  S-Ag-mediated  autoimmunity  are  involved  in  the
pathogenesis of BD.
ICS is another ideal approach for assessing single cellular
responses and has been used earlier to study the frequency and
function  of  effector  T  cells  in  BD  patients  [12,19,20].
Following confirmation of S-Ag specific T cells by ELISPOT
in active BD patients, we analyzed their phenotypic feature
using multiparameter FCM for the expression of CD69 (an
early activation marker) and CD45RO (a memory marker) in
active  BD  patients  with  a  response  to  S-Ag.  The  results
showed that memory CD4  T  cells were the source of S-Ag
specific T cells. Although the stimulated CD8+ T cells also
produced a little amount of IFN-γ, most of them were CD69-
T cells. Therefore these cells were presumed as nonspecific
effector lymphocytes [21]. It is worthy to point out that only
approximately 50% of the active BD patients with a response
to S-Ag showed IFN-γ producing cells detected by FCM. This
may be due to a relatively lower sensitivity of FCM than
ELISPOT to detect the antigen-specific cellular response. It
is regrettable that the phenotype of S-Ag specific T cells in
inactive BD patients could not be investigated due to the
unavailability of blood samples.
An excessive Th1 response involving the pathogenesis of
BD  has  been  demonstrated,  mainly  by  using  polyclonal
stimuli [20,22,23]. Recently, studies have disclosed that Th17
cells  contribute  to  autoimmune  uveitis  [24,25]  and
experimental autoimmune uveitis (EAU) [26]. Data from our
laboratory have shown that IL-23 promotes CD4+ T cells to
produce IL-17 in BD patients [27]. A question is raised as to
whether S-Ag specific T cells play a role through the Th17
response  pathway.  Therefore,  we  compared  the  cytokine
profiles of Th1, Th2, and Th17 after stimulation with S-Ag
peptides. Our results showed that the lymphocytes mainly
showed a Th1 response as evidenced by a notable production
of IFN-γ and TNF-α but little production of IL-17. Due to the
highly heterogeneous cytokine production by individuals and
limited sample size, there was no statistical correlation on
cytokine yield between IFN-γ and TNF-α or between IFN-γ
and  IL-17.  The  interesting  tendencies  outlined  offered  us
some helpful information. The IL-17 level was not coincident
with the Th1 cytokines in active BD patients with or without
a response to S-Ag. This result may suggest that the S-Ag
specific Th1 and Th17 cells play different roles in Behcet’s
uveitis. It may support the notion that a high level of IFN-γ
may inhibit the generation of an IL-17 response [25,26]. The
elevated TNF-α level in all active BD patients both with and
without a response to S-Ag suggests that the TNF-α level
might be an indication of  disease activity.  Studies with large
group of patients may shed more light on this issue.
In summary, a low frequency of S-Ag specific T cells was
displayed by ELISPOT assay in certain BD patients for the
first time. This antigen specific response was evidenced by
the presence of activated memory CD4+ IFN-γ+ T cells and a
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+significant production of IFN-γ and TNF-α by PBMCs. These
results suggest that S-Ag specific T cells may be involved in
the  pathogenesis  of  BD  via  producing  Th1-dominant
cytokines. As the information on the treatments of active
patients was not exactly known, we were not able to determine
whether the responsiveness to S-Ag as well as the phenotype
and cytokine profiles of S-Ag specific T cells were affected
by individual treatment history of each patient or not. Further
studies are in progress to map the Th1 cell immunodominant
epitope of S-Ag.
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